Advertisement
New Zealand markets close in 3 hours 11 minutes
  • NZX 50

    11,740.67
    +24.23 (+0.21%)
     
  • NZD/USD

    0.6119
    -0.0003 (-0.06%)
     
  • NZD/EUR

    0.5708
    -0.0001 (-0.03%)
     
  • ALL ORDS

    8,036.50
    -40.40 (-0.50%)
     
  • ASX 200

    7,798.90
    -39.90 (-0.51%)
     
  • OIL

    80.95
    +0.12 (+0.15%)
     
  • GOLD

    2,326.10
    -4.70 (-0.20%)
     
  • NASDAQ

    19,701.13
    +226.51 (+1.16%)
     
  • FTSE

    8,247.79
    -33.76 (-0.41%)
     
  • Dow Jones

    39,112.16
    -299.05 (-0.76%)
     
  • DAX

    18,177.62
    -147.96 (-0.81%)
     
  • Hang Seng

    17,965.07
    -107.83 (-0.60%)
     
  • NIKKEI 225

    39,537.99
    +364.84 (+0.93%)
     
  • NZD/JPY

    97.7040
    +0.0530 (+0.05%)
     

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ADVERTISEMENT

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com